These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The second life of daptomycin: analysis of a successful come-back]. Decousser JW; Doucet Populaire F Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200 [No Abstract] [Full Text] [Related]
6. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis. Pai AB; Pai MP Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703 [TBL] [Abstract][Full Text] [Related]
8. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Chien JW; Kucia ML; Salata RA Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743 [TBL] [Abstract][Full Text] [Related]
9. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Leclercq R Clin Microbiol Infect; 2009 Mar; 15(3):224-31. PubMed ID: 19335370 [TBL] [Abstract][Full Text] [Related]
10. Newer developments in the treatment of Gram-positive infections. Koomanachai P; Crandon JL; Nicolau DP Expert Opin Pharmacother; 2009 Dec; 10(17):2829-43. PubMed ID: 19929705 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Carpenter CF; Chambers HF Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832 [TBL] [Abstract][Full Text] [Related]
13. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Jones RN Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Melzer M; Goldsmith D; Gransden W Clin Infect Dis; 2000 Jul; 31(1):208-9. PubMed ID: 10913433 [No Abstract] [Full Text] [Related]
15. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Deresinski S Clin Infect Dis; 2009 Oct; 49(7):1072-9. PubMed ID: 19725789 [TBL] [Abstract][Full Text] [Related]
16. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341 [TBL] [Abstract][Full Text] [Related]
17. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Steenbergen JN; Alder J; Thorne GM; Tally FP J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Babcock HM; Ritchie DJ; Christiansen E; Starlin R; Little R; Stanley S Clin Infect Dis; 2001 May; 32(9):1373-5. PubMed ID: 11303275 [TBL] [Abstract][Full Text] [Related]
20. [Research advances in vancomycin-resistant enterococcal infections]. Zhang SF Zhonghua Jie He He Hu Xi Za Zhi; 2003 Apr; 26(4):230-2. PubMed ID: 12911021 [No Abstract] [Full Text] [Related] [Next] [New Search]